Maarit Anttila

Dynamic contrast-enhanced MRI to characterize angiogenesis in primary epithelial ovarian cancer: An exploratory study

Lindgren, Auni; Anttila, Maarit; Arponen, Otso; Hamalainen, Kirsi; Kononen, Mervi; Vanninen, Ritva; Sallinen, Hanna. 2023. European journal of radiology. 165:

Greater increases in intratumoral apparent diffusion coefficients after chemoradiotherapy predict better overall survival of patients with cervical cancer

Holopainen, Erikka; Lahtinen, Olli; Könönen, Mervi; Anttila, Maarit; Vanninen, Ritva; Lindgren, Auni. 2023. PLoS ONE. 18:

Neoadjuvant chemotherapy induces an elevation of tumour apparent diffusion coefficient values in patients with ovarian cancer

Reijonen, Milja; Holopainen, Erikka; Arponen, Otso; Könönen, Mervi; Vanninen, Ritva; Anttila, Maarit; Sallinen, Hanna; Rinta-Kiikka, Irina; Lindgren, Auni. 2023. Bmc cancer. 23: . 299

AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in mice

Kujala, Anni; Valkonen, Elina; Sallinen, Hanna; Tuppurainen, Laura; Laakso, Hanne; Ylä-Herttuala, Elias; Liimatainen, Timo; Kujala, Jouni; Jokelainen, Otto; Sironen, Reijo; Anttila, Maarit; Ylä-Herttuala, Seppo. 2022. Frontiers in medicine. 9: . 1018208

Patient functional recovery after a 23-h surgery — a prospective, follow-up study

Ruohoaho, Ulla-Maija; Aaltomaa, Sirpa; Kokki, Hannu; Anttila, Maarit; Kokki, Merja. 2022. Langenbecks archives of surgery. 407: 2133-2142

Postoperative pain in a prospectively assessed surgical short‐stay cohort: A subgroup analysis

Lappalainen, Emma; Ruohoaho, Ulla‐Maija; Kokki, Hannu; Aaltomaa, Sirpa; Anttila, Maarit; Gissler, Mika; Kokki, Merja. 2022. Acta anaesthesiologica scandinavica. 66: 1193-1201

Resilience, pain, and health-related quality of life in gynecological patients undergoing surgery for benign and malignant conditions: a 12-month follow-up study

Isokääntä, Siiri; Ruohoaho, Ulla Maija; Anttila, Maarit; Kokki, Hannu; Sintonen, Harri; Toroi, Petri; Kokki, Merja. 2022. Bmc womens health. 22: . 345

Microvessels in Epithelial Ovarian Tumors: High Microvessel Density Is a Significant Feature of Malignant Ovarian Tumors

Sopo, Minna; Anttila, Maarit; Muukkonen, Oona-Tuuli; Ylä-Herttuala, Seppo; Kosma, Veli-Matti; Keski-Nisula, Leea; Sallinen, Hanna. 2020. Anticancer research. 40: 6923-6931

Dynamic contrast-enhanced perfusion parameters in ovarian cancer: Good accuracy in identifying high HIF-1α expression

Lindgren, A; Anttila, M; Rautiainen, S; Arponen, O; Hämäläinen, K; Könönen, M; Vanninen, R; Sallinen, H. 2019. PLoS ONE. 14: e0221340

Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer

Sopo, M; Anttila, M; Hämäläinen, K; Kivelä, A; Ylä-Herttuala, S; Kosma, VM; Keski-Nisula, L; Sallinen, H. 2019. Bmc cancer. 19: 584

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Mirza, Mansoor Raza; Lundqvist, Elisabeth Avail; Birrer, Michael; Christensen, Rene DePont; Nyvang, Gitte-Bettina; Malander, Susanne; Anttila, Maarit; Werner, Theresa L; Lund, Bente; Lindahl, Gabriel; Hietanen, Sakari; Peen, Ulla; Dimoula, Maria; Roed, Henrik; Knudsen, Anja Or; Staff, Synnove; Vistisen, Anders Krog; Bjorge, Line; Mäenpää, Johanna U. 2019. The Lancet Oncology. 20: 1409-1419

Prognostic Value of Preoperative Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Epithelial Ovarian Cancer

Lindgren, Auni; Anttila, Maarit; Arponen, Otso; Rautiainen, Suvi; Könönen, Mervi; Vanninen, Ritva; Sallinen, Hanna. 2019. European journal of radiology. 115: 66-73

Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI

Lindgren A, Anttila M, Rautiainen S, Arponen O, Kivelä A, Mäkinen P, Härmä K, Hämäläinen K, Kosma V-M, Ylä-Herttuala S, Vanninen R, Sallinen H. 2017. European radiology. 27: 4002-4012

Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer

Sallinen H, Heikura T, Koponen J, Kosma VM, Heinonen S, Ylä-Herttuala S, Anttila M. 2014. Bmc cancer. 14: 1-10

Preclinical Safety, Toxicology, and Biodistribution Study of Adenoviral Gene Therapy with sVEGFR-2 and sVEGFR-3 Combined with Chemotherapy for Ovarian Cancer

Tuppurainen L, Sallinen H, Kokki E, Koponen J, Anttila M, Pulkkinen K, Heikura T, Toivanen P, Hämäläinen K, Kosma VM, Heinonen S, Alitalo K, Ylä-Herttuala S. 2013. Human gene therapy. clinical development. 24: 29-37

Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma

Sopo M, Anttila M, Sallinen H, Tuppurainen L, Laurema A, Laidinen S, Hamalainen K, Tuunanen P, Koponen JK, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S. 2012. International journal of cancer. 131: 234-2401

Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.

Vuorela M, Pylkäs K, Hartikainen JM, Sundfeldt K, Lindblom A, von Wachenfeldt Wäppling A, Haanpää M, Puistola U, Rosengren A, Anttila M, Kosma VM, Mannermaa A, Winqvist R.. 2011. Breast cancer research and treatment. 130: 1003-10

Hyaluronan in human malignancies

Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M & Kosma VM. 2011. Experimental cell research. 317: 383-391

Munasarjakystat - tarvitseeko aina leikata tai edes seurata?

Kuivasaari-Pirinen P, Anttila M. 2011. Duodecim. 127: 1857-1863

VEGFR-1 and -3 and angiopoietin receptor Tie2 targeted gene therapy prevents the growth of solid human ovarian cancer in mice compared to cotargeting Tie1 and Tie2

Sallinen H, Anttila M, Gröhn O, Koponen J, Hämäläinen K, Kholova I, Heikura T, Kosma VM, Heinonen S, Alitalo K, Ylä-Herttuala S. 2011. Cancer gene therapy. 18: 100-9

Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice

Sallinen H, Anttila M, Gröhn O, Koponen J, Hämäläinen K, Kholova I, Kosma VM, Heinonen S, Alitalo K & Ylä-Herttuala S. 2010. Cancer gene therapy. 18: 100-109

Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma

Nykopp TK, Rilla K, Tammi MI, Tammi RH, Sironen R, Hämäläinen K, Kosma V-M, Heinonen S & Anttila M. 2010. Bmc cancer. 10: 512

Preoperative angiopoietin-2 serum levels. A marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer

Sallinen H, Heikura T, Laidinen S, Kosma V-M, Heinonen S, Ylä-Herttuala S & Anttila M. 2010. International journal of gynecological cancer. 20: 1498-1505

Antiangiogenic gene therapy with soluble VEGFR-1, -2 and -3 reduces the growth of solid human ovarian carcinoma in mice

Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma V-M, Heinonen S, Alitalo K, Yla-Herttuala S. 2009. Molecular therapy. 17: 278-284

Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYALI and hyaluronan content

Nykopp TK, Rilla K, Sironen R, Tammi MI, Tammi RH, Hämäläinen K, Heikkinen A-M, Komulainen M, Kosma V-M, Anttila M. 2009. Bmc cancer. 9: [9 p.]

Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression

Tuhkanen H, Soini Y, Kosma V-M, Anttila M, Sironen R, Hämäläinen K, Kukkonen L, Virtanen I, Mannermaa A. 2009. Bmc cancer. 9:

Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer

Sillanpää S, Anttila M, Suhonen K, Hämäläinen K, Turpeenniemi-Hujanen T, Puistola U, Tammi M, Sironen R, Saarikoski S, Kosma VM. 2007. Tumor biology. 28: 280-289

Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer

Sillanpää S, Anttila M, Voutilainen K, Ropponen K, Turpeenniemi-Hujanen T, Puistola U, Tammi R, Tammi M, Sironen R, Saarikoski S, Kosma V-M. 2007. Gynecologic oncology. 104: 296-303

A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up

Sallinen H, Anttila M, Narvainen J, Ordén M-R, Ropponen K, Kosma V-M, Heinonen S, Yla-Herttuala S. 2006. Gynecologic oncology. 103: 315-320

Frequent gene dosage alterations in stromal cells of epithelial ovarian carcinomas

Tuhkanen H, Anttila M, Kosma V-M, Heinonen S, Juhola M, Helisalmi S, Kataja V, Mannermaa A, Helisalmi S. 2006. International journal of cancer. 119: 1345-1353

Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer

Voutilainen KA, Anttila MA, Sillanpää SM, Ropponen KM, Saarikoski SV, Juhola MT, Kosma V-M. 2006. Journal of clinical pathology. 59: 460-467

Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression

Sillanpää SM, Anttila MA, Voutilainen KA, Ropponen KM, Sironen RK, Saarikoski SV, Kosma V-M. 2006. International journal of cancer. 119: 1792-1799

Effect of endometriosis on IVF/ICSI outcome: stage III/IV endometriosis worsens cumulative pregnancy and live-born rates

Kuivasaari P, Hippeläinen M, Anttila M, Heinonen S. 2005. Human reproduction. 20: 3130-3135

Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p

Tuhkanen H, Anttila M, Kosma V-M, Ylä-Herttuala S, Heinonen S, Kuronen A, Juhola M, Tammi R, Tammi M, Mannermaa A. 2004. International journal of cancer. 109: 247-252

Marked allelic imbalance on chromosome 5q31 does not explain a-catenin expression in epithelial ovarian cancer

Tuhkanen H, Anttila M, Kosma V-M, Puolakka J, Juhola M, Heinonen S, Mannermaa A. 2004. Gynecologic oncology. 94: 416-421

Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis

Voutilainen K, Anttila M, Sillanpää S, Tammi R, Tammi M, Saarikoski S, Kosma V-M. 2003. International journal of cancer. 107: 359-364

Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors

Hiltunen ELJ, Anttila M, Kultti A, Ropponen K, Penttinen J, Yliskoski M, Kuronen AT, Juhola M, Tammi R, Tammi M, Kosma V-M. 2002. Cancer research. 62: 6410-6413

Reproductive risk factors, doppler findings, and outcome of affected births in placental abruption: a population-based analysis

Toivonen S, Heinonen S, Anttila M, Kosma V-M, Saarikoski S. 2002. American journal of perinatology. 19: 451-459

Biological Predictors of Disease Progression and Patient Survival in Epithelial Ovarian Cancer

Anttila M. 2000. Kuopio University Publications D. Medical Sciences

Expression of transcription factor AP-2 alfa predicts survival in epithelial ovarian cancer

Anttila MA, Kellokoski JK, Moisio KI, Mitchell PJ, Saarikoski S, Syrjänen K, Kosma V-M. 2000. British journal of cancer. 82: 1974-1983

Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables

Launonen V, Mannermaa A, Stenbäck F, Kosma V-M, Puistola U, Huusko P, Anttila M, Bloigu R, Saarikoski S, Kauppila A, Winqvist R. 2000. Cancer genetics and cytogenetics. 122: 49-54

Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR

Anttila M, Syrjänen S, Ji H, Saarikoski S, Syrjänen K. 1999. Gynecologic oncology. 72: 337-341

The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer

Anttila MA, Ji H, Juhola MT, Saarikoski SV, Syrjänen KJ. 1999. International journal of gynecological pathology. 18: 42-51

p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer

Anttila MA, Kosma V-M, Hongxiu J, Puolakka J, Juhola M, Saarikoski S, Syrjänen K. 1999. British journal of cancer. 79: 1870-1878

Clinical significance of alfa-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer

Anttila M, Kosma V-M, Ji H, Wei-Ling X, Puolakka J, Juhola M, Saarikoski S, Syrjänen K. 1998. Journal of clinical oncology. 16: 2591-2600

Tarkenna hakuasi

Dynamic contrast-enhanced MRI to characterize angiogenesis in primary epithelial ovarian cancer: An exploratory study

Greater increases in intratumoral apparent diffusion coefficients after chemoradiotherapy predict better overall survival of patients with cervical cancer

Neoadjuvant chemotherapy induces an elevation of tumour apparent diffusion coefficient values in patients with ovarian cancer

AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in mice

Patient functional recovery after a 23-h surgery — a prospective, follow-up study

Postoperative pain in a prospectively assessed surgical short‐stay cohort: A subgroup analysis

Resilience, pain, and health-related quality of life in gynecological patients undergoing surgery for benign and malignant conditions: a 12-month follow-up study

Microvessels in Epithelial Ovarian Tumors: High Microvessel Density Is a Significant Feature of Malignant Ovarian Tumors

Dynamic contrast-enhanced perfusion parameters in ovarian cancer: Good accuracy in identifying high HIF-1α expression

Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Prognostic Value of Preoperative Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Epithelial Ovarian Cancer

Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI

Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer

Preclinical Safety, Toxicology, and Biodistribution Study of Adenoviral Gene Therapy with sVEGFR-2 and sVEGFR-3 Combined with Chemotherapy for Ovarian Cancer

Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma

Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.

Hyaluronan in human malignancies

Munasarjakystat - tarvitseeko aina leikata tai edes seurata?

VEGFR-1 and -3 and angiopoietin receptor Tie2 targeted gene therapy prevents the growth of solid human ovarian cancer in mice compared to cotargeting Tie1 and Tie2

Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice

Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma

Preoperative angiopoietin-2 serum levels. A marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer

Antiangiogenic gene therapy with soluble VEGFR-1, -2 and -3 reduces the growth of solid human ovarian carcinoma in mice

Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYALI and hyaluronan content

Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression

Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer

Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer

A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up

Frequent gene dosage alterations in stromal cells of epithelial ovarian carcinomas

Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer

Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression

Effect of endometriosis on IVF/ICSI outcome: stage III/IV endometriosis worsens cumulative pregnancy and live-born rates

Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p

Marked allelic imbalance on chromosome 5q31 does not explain a-catenin expression in epithelial ovarian cancer

Obstetric prognosis after placental abruption

CD44 expression indicates favorable prognosis in epithelial ovarian cancer

Obstetric outcome in women with endometriosis-a matched case-control study

Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis

Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors

Reproductive risk factors, doppler findings, and outcome of affected births in placental abruption: a population-based analysis

Biological Predictors of Disease Progression and Patient Survival in Epithelial Ovarian Cancer

Expression of transcription factor AP-2 alfa predicts survival in epithelial ovarian cancer

Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables

Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR

The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer

p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer

Clinical significance of alfa-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer